

JFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Donald W. Landry and Juan A. Oliver
Serial No.: 10/789,548
Filed: February 26, 2004
Docket: 30000.2USU1
Title: A METHOD FOR STABILIZING BLOOD PRESSURE IN HEMODIALYSIS SUBJECTS

CERTIFICATE UNDER 37 CFR §1.8

I hereby certify that this paper or fee is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on October 19, 2004.

By: Renato Marco P. Domingo
Name: Renato Marco P. Domingo

55 S. Lake Avenue, Suite 710
Pasadena, California 91101
October 19, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal sheet, in duplicate, containing Certificate under 37 CFR §1.8
- ☒ Supplemental Information Disclosure Statement (37 C.F.R. §1.97(b)(3)) (2 pages)
- ☒ Form 1449 (Information Disclosure Statement) (1 sheet)
- ☒ Exhibits 74-76 (References)
- ☒ Return postcard

Please charge any additional fees or credit overpayment to Deposit Account No. 50-0306. A duplicate of this sheet is enclosed.

MANDEL & ADRIANO

55 S. Lake Avenue, Suite 710
Pasadena, California 91101
(626) 395-7801

By: Sarah B. Adriano
Name: Sarah B. Adriano
Reg. No.: 34,470
Customer No. 26,941



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Donald W. Landry and Juan A. Oliver **Examiner:** Not yet known
Serial No.: 10/789,548 **Group Art Unit:** 3762
Filed: February 26, 2004 **Docket No.:** 30000.2USU1
Title: A METHOD FOR STABILIZING BLOOD PRESSURE IN HEMODIALYSIS SUBJECTS

CERTIFICATE UNDER 37 CFR §1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on October 19, 2004.

Renato Marco P. Domingo

By: Renato Marco P. Domingo

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b)(3))

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

This Information Disclosure Statement is being filed herein as a supplement to Applicant's August 11, 2004 and September 17, 2004 Information Disclosure Statement which was submitted under 37 C.F.R. §1.97(b)(3) before the mailing date of the first Office Action on the merits. In accordance with 37 C.F.R. §1.98(d), copies of Exhibits 74-76 as set forth in the Form 1449 are included herein.

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. They are as follows:

- U.S. Patent No. 5,906,974 issued May 25, 1999 – **Exhibit 74**
- Jarcuska, P. et al., "Hemodialysis in Hepatorenal Syndrome Type 1 in Alcoholic Liver Cirrhosis Treated by Continual Terlipressin Infusion in Combination with Albumin Plasmaexpansion," *Journal of Hepatology*, 2003, 38:194-5, Abstract #675 – **Exhibit 75**


- Lindberg, Jill S. et al., "Lysine Vasopressin (LV) in the Treatment of Refractory Hemodialysis Induced Hypotension (HIH)," *Kidney International*, 1988, 33:229 – **Exhibit 76**

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that the references have been thoroughly reviewed or that any relevance of any portion of a reference is intended.


Consideration of the items listed is respectfully requested. Applicants invite the Patent Office to request additional information if necessary. Pursuant to the provisions of M.P.E.P. § 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee, or credit any overpayment, to Deposit Account No. 50-0306.

Respectfully submitted,



Sarah B. Adriano
Registration No. 34,470
SaraLynn Mandel
Registration No. 31,853
Mandel & Adriano
55 S. Lake Avenue, Suite 710
Pasadena, California 91101
(626) 395-7801
Customer No. 26,941

FORM 1449* 	Docket Number 30000.2USU1	Application Number 10/789,548
	Applicants Donald W. Landry and Juan A. Oliver	
	Filing Date February 26, 2004	Group Art Unit 3762

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,906,974 (Exhibit 74)	05/25/99	Blue et al.			08/21/96

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Jarcuska, P. et al., "Hemodialysis in Hepatorenal Syndrome Type 1 in Alcoholic Liver Cirrhosis Treated by Continual Terlipressin Infusion in Combination with Albumin Plasmaexpansion," <i>Journal of Hepatology</i> , 2003, 38:194-5, Abstract #675 (Exhibit 75)
		Lindberg, Jill S. et al., "Lysine Vasopressin (LV) in the Treatment of Refractory Hemodialysis Induced Hypotension (HIH)," <i>Kidney International</i> , 1988, 33:229 (Exhibit 76)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	